title: Primary bone marrow diffuse large B-cell lymphoma affecting distal parts of the legs as a cause of persisting B symptoms.
authors.affiliation: Department of Nuclear Medicine, Universitätsklinikum, Würzburg, Germany.
authors.forename: Constantin
authors.initials: C
authors.lastname: Lapa
authors.forename: Markus
authors.initials: M
authors.lastname: Knott
authors.forename: Leo
authors.initials: L
authors.lastname: Rasche
authors.forename: Ken
authors.initials: K
authors.lastname: Herrmann
authors.forename: Andreas K
authors.initials: AK
authors.lastname: Buck
authors.forename: Andreas
authors.initials: A
authors.lastname: Rosenwald
mesh_terms: D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001706:Biopsy; D001853:Bone Marrow / Q000473:pathology*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D019788:Fluorodeoxyglucose F18; D006801:Humans; D007866:Leg; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology*; D049268:Positron-Emission Tomography; D011241:Prednisone / Q000627:therapeutic use; D000069283:Rituximab; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; C571759:R-CHOP protocol; D019788:Fluorodeoxyglucose F18; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone